Literature DB >> 23730937

Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety.

Christine Hiller1, Ralf C Kling, Frank W Heinemann, Karsten Meyer, Harald Hübner, Peter Gmeiner.   

Abstract

Dopaminergics of types 1 and 2 incorporating a conjugated enyne as an atypical catechol-simulating moiety were synthesized in enantiomerically pure form and investigated for their metabolic stability. Radioligand binding studies indicated high affinity to D2-like receptors. The test compounds were evaluated for their ability to differentially activate distinct signaling pathways. Measurement of D(2L)- and D(2S)-mediated [(35)S]GTPγS incorporation in the presence of coexpressed Gα(o) and Gα(i) subunits showed significantly biased receptor activation for several test compounds. Thus, the 2-azaindolylcarboxamide (S)-2a exhibited substantial functional selectivity for D(2S)-promoted G(o) activation over G(i) coupling. The most significant bias was determined for the triazolylalkoxy-substituted benzamide (S)-2c that displayed higher potency for G(o) activation than for G(i) coupling at the D(2L) subtype. Functional selectivity for β-arrestin recruitment over G(i) activation was observed for the biphenylcarboxamide (R)-1 and the 2-benzothiophenylcarboxamide (S)-2d, whereas the 2-substituted azaindole (S)-2a preferred β-arrestin recruitment compared to G(o) coupling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23730937     DOI: 10.1021/jm400520c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.

Authors:  Yudao Shen; John D McCorvy; Michael L Martini; Ramona M Rodriguiz; Vladimir M Pogorelov; Karen M Ward; William C Wetsel; Jing Liu; Bryan L Roth; Jian Jin
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

Review 2.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

3.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

4.  A kinetic view of GPCR allostery and biased agonism.

Authors:  J Robert Lane; Lauren T May; Robert G Parton; Patrick M Sexton; Arthur Christopoulos
Journal:  Nat Chem Biol       Date:  2017-08-18       Impact factor: 15.040

5.  Structure-based discovery of opioid analgesics with reduced side effects.

Authors:  Aashish Manglik; Henry Lin; Dipendra K Aryal; John D McCorvy; Daniela Dengler; Gregory Corder; Anat Levit; Ralf C Kling; Viachaslau Bernat; Harald Hübner; Xi-Ping Huang; Maria F Sassano; Patrick M Giguère; Stefan Löber; Grégory Scherrer; Brian K Kobilka; Peter Gmeiner; Bryan L Roth; Brian K Shoichet
Journal:  Nature       Date:  2016-08-17       Impact factor: 49.962

6.  Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists.

Authors:  Xin Chen; John D McCorvy; Matthew G Fischer; Kyle V Butler; Yudao Shen; Bryan L Roth; Jian Jin
Journal:  J Med Chem       Date:  2016-11-16       Impact factor: 7.446

7.  A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity.

Authors:  Marta Sanchez-Soto; Ravi Kumar Verma; Blair K A Willette; Elizabeth C Gonye; Annah M Moore; Amy E Moritz; Comfort A Boateng; Hideaki Yano; R Benjamin Free; Lei Shi; David R Sibley
Journal:  Sci Signal       Date:  2020-02-04       Impact factor: 8.192

8.  Bioluminescence Resonance Energy Transfer Assay to Characterize Gi-Like G Protein Subtype-Dependent Functional Selectivity.

Authors:  Hideaki Yano; Marta Sánchez-Soto; Sergi Ferré
Journal:  Curr Protoc Neurosci       Date:  2017-10-23

9.  Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.

Authors:  Michael L Martini; Caroline Ray; Xufen Yu; Jing Liu; Vladimir M Pogorelov; William C Wetsel; Xi-Ping Huang; John D McCorvy; Marc G Caron; Jian Jin
Journal:  ACS Chem Neurosci       Date:  2019-08-20       Impact factor: 4.418

10.  Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.

Authors:  Thomas M Keck; William S John; Paul W Czoty; Michael A Nader; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-03-31       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.